Promising triple-drug combo aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07351487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left at surgery. This is an early-phase trial, so while results are promising, the treatment is not yet proven and may have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers
- New combo attack on aggressive breast cancer brain tumors shows promise in early trial